Cargando…
An In Vivo Platform for Tumor Biomarker Assessment
Tumor biomarkers provide a quantitative tool for following tumor progression and response to therapy. However, investigations of clinically useful tumor biomarkers are time-consuming, costly, and limited by patient and tumor heterogeneity. In addition, assessment of biomarkers as indicators of thera...
Autores principales: | Servais, Elliot L., Suzuki, Kei, Colovos, Christos, Rodriguez, Luis, Sima, Camelia, Fleisher, Martin, Rusch, Valerie W., Sadelain, Michel, Adusumilli, Prasad S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202552/ https://www.ncbi.nlm.nih.gov/pubmed/22046338 http://dx.doi.org/10.1371/journal.pone.0026722 |
Ejemplares similares
-
Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1
por: Eguchi, Takashi, et al.
Publicado: (2017) -
Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice
por: Offin, Michael, et al.
Publicado: (2022) -
Commentary: Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice
por: Hocine, Hocine Rachid, et al.
Publicado: (2020) -
Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients
por: Volpe, Alessia, et al.
Publicado: (2022) -
Nuclear estrogen receptor-α expression is an independent predictor of recurrence in male patients with pT1aN0 lung adenocarcinomas, and correlates with regulatory T-cell infiltration
por: Kadota, Kyuichi, et al.
Publicado: (2015)